This is a regulatory filing submitted to the National Stock Exchange of India Limited and BSE Limited. It serves as an addendum to a previous intimation dated June 29, 2026, regarding a scheduled meeting of the Board of Directors.
The Board meeting is scheduled for Friday, July 24, 2026. The agenda for the meeting includes two key items:
- Consideration and approval of the unaudited financial results for the quarter ended June 30, 2026. The results will be reviewed on both a Standalone and Consolidated basis.
- Consideration of an Interim Dividend, if any, on the Equity Shares of the Company for the Financial Year 2026-27.
The document is signed by Vinay Gujral, who holds the titles of Company Secretary and Compliance Officer for Dr. Lal PathLabs Limited. The document was digitally signed on July 17, 2026, at 13:02:41 IST.
The financial impact of a potential dividend is not quantified in this disclosure, as its declaration is pending board approval.